The results from work done at the Centre of Translational Research in Cancer of the Jewish General Hospital in Montreal showed a potent delay of tumor growth following administration of WBI-2100.
The results are consistent with those from in vitro and in vivo studies on WBI-2100 conducted by the US National Cancer Institute. WBI-2100, a fully synthesized, small molecule compound, delayed the growth of common cancers such as breast, ovary and colon.
“These positive results of WBI-2100, in studies from different research laboratories are very encouraging, and the nature of the data open-up potential for use of this novel agent alone or in conjunction with existing therapies” said president and CEO Dr John Webster.
Welichem’s compounds in the WBI-2000 series are tested, under a November, 1996 screening agreement, with the Cancer Treatment and Diagnosis Division of National Cancer Institute, the principal agency for cancer research of the US government.